Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Inbar

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Gynecologic Oncology|May 19, 2009
Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinomaTamar Safra, Joseph Menczer, Rinat Molho Bernstein, et al.
Melanoma Research|January 25, 2006
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II studyIlan G Ron, David Sarid, Larisa Ryvo, et al.
Gynecologic and Obstetric Investigation|September 20, 2007
The complexity of management of pregnancy-associated malignant soft tissue and bone tumorsRinat Bernstein Molho, Yehuda Kollender, Josephine Issakov, et al.
British Journal of Cancer|December 15, 2015
Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancerChristoph Zielinski, Istvan Lang, Semir Beslija, et al.
Oncology|December 14, 2011
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trialTamar Safra, Rinat Bernstein-Molho, Julia Greenberg, et al.
American Journal of Clinical Oncology|October 24, 2002
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroupsIlan G Ron, Nely Wigler, Riva Borovik, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancerI Lang, M J Inbar, Z Kahán, et al.
American Journal of Clinical Oncology|July 28, 2001
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter studyI G Ron, N Wigler, R Borovik, et al.
British Journal of Cancer|October 1, 2014
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analysesT Brodowicz, I Lang, Z Kahan, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Gynecologic Oncology|May 19, 2009
Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinomaTamar Safra, Joseph Menczer, Rinat Molho Bernstein, et al.
Melanoma Research|January 25, 2006
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II studyIlan G Ron, David Sarid, Larisa Ryvo, et al.
Gynecologic and Obstetric Investigation|September 20, 2007
The complexity of management of pregnancy-associated malignant soft tissue and bone tumorsRinat Bernstein Molho, Yehuda Kollender, Josephine Issakov, et al.
British Journal of Cancer|December 15, 2015
Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancerChristoph Zielinski, Istvan Lang, Semir Beslija, et al.
Oncology|December 14, 2011
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trialTamar Safra, Rinat Bernstein-Molho, Julia Greenberg, et al.
American Journal of Clinical Oncology|October 24, 2002
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroupsIlan G Ron, Nely Wigler, Riva Borovik, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancerI Lang, M J Inbar, Z Kahán, et al.
American Journal of Clinical Oncology|July 28, 2001
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter studyI G Ron, N Wigler, R Borovik, et al.
British Journal of Cancer|October 1, 2014
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analysesT Brodowicz, I Lang, Z Kahan, et al.
Pageof 4